MedPath

WallFlex Biliary Fully Covered (FC) Benign Stricture Study

Phase 3
Completed
Conditions
Biliary Stricture
Interventions
Device: WallFlex Biliary RX Fully Covered Stent System
Registration Number
NCT01014390
Lead Sponsor
Boston Scientific Corporation
Brief Summary

The purpose of this study is to evaluate the safety and performance of the WallFlex® Biliary RX Fully Covered Stent as a treatment of biliary obstruction resulting from benign bile duct strictures.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
187
Inclusion Criteria
  • Age 18 or older
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study
  • Chronic pancreatitis or prior liver transplantation or prior other abdominal surgery (to include cholecystectomy)
  • Indicated for ERCP procedure with stent placement for: Symptomatic bile duct stricture (i.e. obstructive jaundice, persistent cholestasis, acute cholangitis) confirmed by cholangiogram and/or Bile duct stricture confirmed by cholangiogram and/or Exchange of prior plastic stent(s) for management of benign stricture
Exclusion Criteria

General:

  • Placement of the stent in strictures that cannot be dilated enough to pass the delivery system
  • Placement of the stent in a perforated duct
  • Placement of the stent in very small intrahepatic ducts
  • Patients for whom endoscopic techniques are contraindicated
  • Biliary stricture of malignant etiology
  • Biliary stricture of benign etiology other than chronic pancreatitis or liver transplant anastomosis or other abdominal surgery
  • Stricture within 2 cm of duct bifurcation
  • Symptomatic duodenal stenosis (with gastric stasis)
  • Prior biliary self-expanding metal stent
  • Suspected stricture ischemia based on imaging of hepatic artery occlusion or endoscopic evidence of biliary cast syndrome
  • Known bile duct fistula
  • Known sensitivity to any components of the stent or delivery system
  • Participation in another investigational study within 90 days prior to consent or during the study

Additional Specific to Chronic Pancreatitis Patients:

  • Developing obstructive biliary symptoms associated with an attack of acute pancreatitis

Additional Specific to Post-Abdominal Surgery Patients:

  • History of hepatectomy
  • History of liver transplant

Additional Specific to Liver Transplant Patients:

  • Live donor transplantation

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
WallFlex Biliary RX FC Stent SystemWallFlex Biliary RX Fully Covered Stent SystemThe WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
Primary Outcome Measures
NameTimeMethod
Stent RemovabilityAt stent removal

Defined as ability to remove the stent endoscopically without serious stent removal related adverse events as assessed from the time of stent removal to 1month post-stent removal.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

Clinica Alemana de Santiago

🇨🇱

Santiago, Chile

Asian Institute of Gastroenterology

🇮🇳

Hyderabad, India

MUHC - McGill University

🇨🇦

Montreal, Quebec, Canada

Medical University of Vienna

🇦🇹

Vienna, Austria

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

ULB Erasme Hospital

🇧🇪

Brussels, Belgium

St. Michael's Hospital

🇨🇦

Toronto, Ontario, Canada

Hopital Edouard Herriot

🇫🇷

Lyon, France

Centre Hospitalier de l'Université de Montréal-Saint-Luc Hospital

🇨🇦

Montreal, Quebec, Canada

Evangelischen Krankenhaus

🇩🇪

Dusseldorf, Germany

Università Cattolica del Sacro Cuore Policlinico A. Gemelli

🇮🇹

Rome, Italy

Hospital Universitari Doctor Josep Trueta

🇪🇸

Girona, Catalunya, Spain

Erasmus Medical Center

🇳🇱

Rotterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath